Axa
BNR

Axa’s Burning Rock Biotech BNR Stock Holding History

Axa’s Portfolio BNR Stock Details BNR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-2,700
Closed -$483K – 1171
2021
Q3 		$483K Hold
2,700
– – ﹤0.01% 1063
2021
Q2 		$795K Hold
2,700
– – ﹤0.01% 1045
2021
Q1 		$727K Sell
2,700
-100
-4% -$30.4K ﹤0.01% 1028
2020
Q4 		$647K Buy
2,800
+800
+40% +$215K ﹤0.01% 1035
2020
Q3 		$502K Buy
+2,000
New +$474K ﹤0.01% 1036

Other funds holding BNR

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Canada Pension Plan Investment Board
Canada Pension Plan Investment Board Toronto Ontario, Ontario, Canada $155B AUM 29.93% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Axa's BNR Position: Q4 2021 in Review

Axa sold out of Burning Rock Biotech (BNR) in Q4 2021, closing a stake of 2,700 shares — an estimated $483K sold.

Axa first reported a position in BNR in Q3 2020 and held it in 5 quarters. The position peaked at $795K in Q2 2021. 62 funds tracked by Wall St. Rank hold BNR as of Q4 2021.

  • Axa reported no remaining Burning Rock Biotech position as of Q4 2021 after selling out during the quarter.
  • Axa sold 2,700 Burning Rock Biotech shares in Q4 2021, an estimated $483K.
  • Axa first reported a position in Burning Rock Biotech in Q3 2020 and held it in 5 quarters.
  • Axa's Burning Rock Biotech position peaked at $795K in Q2 2021.
  • 62 funds tracked by Wall St. Rank held Burning Rock Biotech as of Q4 2021.

Based on Axa's 13F filing for Q4 2021, filed 14 Feb 2022.